FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For …,

(NASDAQ: SRNE, “Sorrento”) announced today that the company has received FDA clearance to proceed with a Phase 2 clinical study of RTX for …, (NASDAQ: SRNE, “Sorrento”) announced today that the company has received FDA clearance to proceed with a Phase 2 clinical study of RTX for …, Read More

Scroll to Top